Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...

“Although not named in this case, all drug manufacturers should be ... adding that the company has not raised list prices for ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

For example, two plans of one insurer list four insulins in ... changes in the coverage of these drugs, which becomes an important concern for those who need insulin. There are probably 12 or ...

accusing them of "engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs, impaired patients’ access to lower list price ...